1/ Was the pandemic caused by SARS2 the result of vaccine research gone wrong? The following thread is the product of a DRASTIC* investigation: the possibility that SARS2 and RaTG13 might be two different vaccine strategies and that SARS2 leaked from a lab during its development.
2/ Which are typical features of a live attenuated vaccine (LAV)? LAV should infect a host with lower virulence and replication capability than the WT, trigger a pronounced adaptive immune response but be cleared quickly without latent infection and it must not revert to its WT.
3/ “Circuit breakers” are required in LAV and the more are integrated into the genome, the safer is the LAV. The resulting fitness attenuation must however retain immunogenicity and protection efficacy against WT challenges.
4/A central mechanism in mammals that controls both innate and adaptive immune responses is mediated by interferons (IFNs). LAV should therefore induce IFN, but rapid clearance after IFN induction would be desirable.
6/ Several viral proteins involved in IFN signalling in SARS2 seem to be affected by attenuation, such as NSP3 (less effective deubiquitinating domain due to 24 AA insertion upstream), ORF3b (premature stop codon)
8/ Bat immortalized kidney cell line RaK4324 expressing hACE could provide the environment for hACE2 adaptation and avoid at the same time IFN response.
9/ Moreover, the QTQTN motive proximal to the FCS is beneficial for virus entry in presence of Cathepsin, which is naturally produced by kidney cells.
https://s3-eu-west-1.amazonaws.com/itempdf74155353254prod/12213125/Targeting_TMPRSS2_and_Cathepsin_B_L_Together_May_Be_Synergistic_Against_SARS-CoV-2_Infection_v1.pdf
10/ Synonymous mutations were used in the past as strategy for attenuating viruses through codon deoptimization. By comparing RaTG13 with SARS2, an accumulation of synonymous mutations in spike around the FCS is clearly observed.
https://www.researchgate.net/publication/6816952_Reduction_of_the_Rate_of_Poliovirus_Protein_Synthesis_through_Large-Scale_Codon_Deoptimization_Causes_Attenuation_of_Viral_Virulence_by_Lowering_Specific_Infectivity
https://jvi.asm.org/content/89/7/3523
11/ Interestingly, the № of CpG dinucleotides of SARS2 is significantly lower than in SARS or MERS and may point as well towards attenuation.
13/ The use of recombination resistant strains is another strategy for LAV development and it can be achieved by manipulating the viral transcription regulatory networks (TRNs).
17/ LAV should also not easily mutate and SARS2 seems to be quite resistant to mutations. This feature might have been achieved by selecting strains with RNA-dependent RNA polymerase (RdRp) with improved fidelity via experiments with mutagenic drugs such as ribavirin.
19/ Moreover, ORF10 is coded by a unique sequence in SARS2 and it is not essential. It is immunogenic and it might contribute in hijacking the host’s ubiquitination machinery but it is truncated and probably not expressed, representing another possible attenuation strategy.
21/ How to explain the presence of the FCS? This site (new for Sarbecovirus) could have been inserted to confer immunity not only to SARS-like CoVs but also to CoVs with FCS, such as MERS.
22/ The FCS in SARS2 has highly CpG-rich insertion (CGG-CGG) which is extremely rare as double instance in CoVs and deoptimizes the codon for replication
https://www.researchgate.net/publication/340924249_Is_considering_a_genetic-manipulation_origin_for_SARS-CoV-2_a_conspiracy_theory_that_must_be_censored
23/ To avoid activation of the FCS, a shield of O-linked glycans was possibly planned, by inserting a leading proline in the sequence, but it failed to be synthetized, probably because of a N-linked glycan site just upstream of the S1-S2, blocking the required glycosyltransferase
25/ If the shield would have been present, not only the FCS would have been blocked but also the activity of Cathepsin and TMPRS2 would have been hampered.
28/ It is not possible to exclude that the original sequence coding for the FCS was designed to be inactive, but it mutated during human to human transmission.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379507/pdf/fgene-11-00783.pdf
29/ Moreover, the FCS of CoV2 matches exactly to that of a Heparan Sulphate binding motif—XBBXBX.
https://www.sciencedirect.com/science/article/pii/S0092867420312307
This particular feature confers to SARS2 the ability to efficiently bind to proteins. https://twitter.com/BillyBostickson/status/1276420129346056198
33/ RaTG13 also presents codon deoptimization. Moreover, its RBM is not able to bind hACE2 and it is not found in any other CoV known. RaTG13 could be therefore the unfinished result of a different vaccine strategy, such as Virus-like particle (VLP).
34/ Development of several vaccine strategies against BtCoV was an active field of research at the WIV and DARPA before SARS2 outbreak. https://twitter.com/BillyBostickson/status/1312049914206056448
35/ Recent ongoing research also involved experiments on self-spreading vaccines. The risk that an unfinished vaccine might have leaked during tests on animal models (e.g. lab worker infection, improper waste disposal) should therefore be not underestimated.
37/ *DRASTIC is a group of independent and not funded researchers working voluntarily together to investigate the origins of SARS2.
https://twitter.com/BillyBostickson/status/1303831074418487296
@CZilcho @ch_zimmer @interne41914499 @schnufi666
38/please unroll @threadreaderapp
You can follow @Rossana38510044.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.